<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475460</url>
  </required_header>
  <id_info>
    <org_study_id>HeartMate 3 LIS</org_study_id>
    <nct_id>NCT02475460</nct_id>
  </id_info>
  <brief_title>HeartMate 3™ LIS Study</brief_title>
  <acronym>HM 3 LIS</acronym>
  <official_title>Thoratec Corporation HeartMate 3™ Less Invasive Surgery (LIS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thoratec Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a less invasive implantation technique of the
      HeartMate 3 Left Ventricular Assist System (HM 3 LVAS) in 10 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the less invasive implantation technique of the HM 3 LVAS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of survival participants</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>HM 3 LIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients implanted with the HM 3 LVAD via less invasive surgical technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Less Invasive Surgery (LIS)</intervention_name>
    <description>Less invasive HM 3 LVAD surgical implant procedure</description>
    <arm_group_label>HM 3 LIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartMate 3™</intervention_name>
    <description>HM 3 LIS</description>
    <arm_group_label>HM 3 LIS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient or legal representative has signed Informed Consent Form (ICF)

          2. Age ≥ 18 years

          3. BSA ≥ 1.2 m2

          4. NYHA IIIB or IV, or ACC/AHA Stage D

          5. LVEF ≤ 25%

          6. CI ≤ 2.2 L/min/m2, while not on inotropes (if Patient is treated with inotropes at
             baseline, this does not apply)

          7. Patients must also meet one of the following:

               -  On optimal medical management (OMM), based on current heart failure practice
                  guidelines for at least 45 out of the last 60 days and are failing to respond, OR

               -  In NYHA class IIIB or IV heart failure for at least 14 days AND dependent on
                  intraaortic balloon pump (IABP) for at least 7 days, OR

               -  Inotrope dependent/unable to wean from inotropes OR

               -  Listed for transplant

          8. Females of child bearing age must agree to use adequate contraception-

        Exclusion Criteria:

          1. Etiology of heart failure (HF) due to or associated with uncorrected thyroid disease,
             obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive
             cardiomyopathy

          2. Technical obstacles which pose an inordinately high surgical risk, in the judgment of
             the Investigator

          3. Existence of ongoing mechanical circulatory support (MCS) other than IABP

          4. Positive pregnancy test if of childbearing potential

          5. Lactating mothers

          6. Presence of mechanical aortic cardiac valve

          7. History of any organ transplant

          8. Platelet count &lt; 100,000 x 103/L (&lt; 100,000/ml)

          9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial
             issues that are likely to impair compliance with the study protocol and LVAS
             management

         10. History of confirmed, untreated AAA &gt; 5 cm in diameter

         11. Presence of an active, uncontrolled infection

         12. Intolerance to anticoagulant or antiplatelet therapies or any other
             peri/post-operative therapy that the Investigator will require based upon the
             patients' health status

         13. Presence of any one of the following risk factors for indications of severe end organ
             dysfunction or failure:

               -  An INR ≥ 2.5 not due to anticoagulation therapy

               -  Total bilirubin &gt; 43 umol/L (2.5 mg/dl), shock liver, or biopsy proven liver
                  cirrhosis

               -  History of severe chronic obstructive pulmonary disease (COPD) defined by
                  FEV1/FVC &lt; 0.7, or FEV1 &lt;50% predicted

               -  Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is
                  unresponsive to pharmacologic intervention

               -  History of stroke within 90 days prior to enrollment, or a history of
                  cerebrovascular disease with significant (&gt; 80%) carotid artery stenosis

               -  Serum Creatinine ≥ 221umol/L (2.5 mg/dl) or the need for chronic renal
                  replacement therapy

               -  Significant peripheral vascular disease (PVD) accompanied by rest pain or
                  extremity ulceration

         14. Aortic valve regurgitation &gt; grade 1

         15. Pre albumin &lt; 150 mg/L, or Albumin &lt; 30g/L (3 g/dL)

         16. Planned Bi-VAD support prior to enrollment

         17. Patient has known hypo or hyper coagulable states such as disseminated intravascular
             coagulation and heparin induced thrombocytopenia

         18. Planned concomitant intra-cardiac cardiac surgery

         19. Thrombus formation in the atrium or left ventricle identified by echocardiogram

         20. Previous sternotomy or left-sided thoracotomy

         21. Participation in any other clinical investigation that is likely to confound study
             results or affect the study

         22. Any condition other than HF that could limit survival to less than 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Damme, BSN, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Thoratec Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>4</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HeartMate 3</keyword>
  <keyword>LVAS</keyword>
  <keyword>LVAD</keyword>
  <keyword>Heart-assist Devices</keyword>
  <keyword>Advanced</keyword>
  <keyword>Ventricular Dysfunction</keyword>
  <keyword>refractory left ventricular</keyword>
  <keyword>Thoratec Corporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

